The Veea Inc. (NASDAQ: VEEA) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Veea’s capital structure, securities listings, and material corporate events that complement the company descriptions found in its press releases.
Veea’s Form 8‑K dated October 2, 2025, for example, discloses that the company received notices from The Nasdaq Stock Market LLC regarding noncompliance with several continued listing standards, including the minimum bid price requirement, the minimum market value of publicly held shares requirement, and the market value of listed securities requirement for the Nasdaq Global Market. The filing explains that these notices had no immediate effect on the listing of Veea’s common stock (VEEA) and publicly tradable warrants (VEEAW), and describes the 180‑day compliance periods and potential options available under Nasdaq rules.
Through this page, users can review current and historical filings such as Forms 8‑K, registration statements on Form S‑1 referenced in Veea’s offering announcements, and other periodic or transactional reports that Veea submits as a Nasdaq‑listed issuer and emerging growth company. These documents can shed light on topics such as public offerings of common stock and warrants, use of proceeds, changes in capital structure, and notices related to listing standards.
Stock Titan enhances access to these filings with tools designed to make lengthy documents easier to navigate. Users can quickly locate key sections related to listing status, securities descriptions, and other material disclosures. Real‑time updates from the SEC’s EDGAR system help ensure that new Veea filings, including additional 8‑Ks, registration statements, or other required reports, appear on this page as they become available.
Veea Inc. (VEEA) director Helder Antunes resigned from the board effective immediately on October 8, 2026, and will continue as the company’s Executive Vice President and Chief Revenue Officer. Veea stated that his resignation was not the result of disagreements with management or the board about the company’s operations, policies, or practices.
Effective October 8, 2026, director Alan Black was appointed to the board’s Compensation Committee. After Antunes’s resignation, the board unanimously approved reducing its size to five members.
Veea Inc. appointed director Kanishka Roy to serve on its Audit Committee, effective October 6, 2026.
Veea Inc. received four unsecured loans from NLabs Inc., a principal stockholder and an affiliate of Veea’s Chief Executive Officer, on September 29, 2026: three notes with principal of $500,000 each and one note with principal of $150,000. The notes accrue interest at an annual rate of 10%, calculated using a 365-day year and actual days elapsed. Principal and accrued interest are payable upon the earlier of December 31, 2026, or demand by NLabs. Veea may prepay the notes in whole or in part without penalty at any time, and the proceeds are for working capital.
VEEA Inc. (VEEA) reported that it has signed a non-binding term sheet with NovaGen Group B.V. for a proposed business combination that would create NovaGen Health Networks, a global health platform combining Veea’s edge AI infrastructure and HealthLynx with NovaGen’s regenerative medicine and longevity services. The parties aim to sign a definitive agreement within the coming weeks, but the transaction is subject to due diligence, shareholder and regulatory approvals, and other closing conditions, and may not be completed. In a related press release, GeoNova Capital signed a term sheet to provide an initial US$10 million investment in the combined company, and Veea’s management cites internal projections and an independent valuation indicating an approximate $750 million value for the combined entity, with initial NovaGen Health Networks deployments targeted for Q4 2026.
Veea Inc. (VEEA) entered into related‑party financing and approved a significant capital structure change. On August 26, 2026, NLabs Inc., a principal stockholder and affiliate of Veea’s CEO, made three unsecured loans to Veea via Demand Promissory Notes totaling $1,150,000, bearing 10% annual interest and payable on the earlier of December 31, 2026 or demand; proceeds are for working capital.
The board approved a 1‑for‑20 reverse stock split of Veea’s common stock, with effectiveness at 4:30 p.m. Eastern Time on August 28, 2026 and split‑adjusted trading expected to begin August 31, 2026. Every 20 issued and outstanding common shares will convert into 1 share, with fractional shares rounded up. Public warrants will be adjusted so each warrant represents 1/20 of one common share at an exercise price of $230.00 per whole share, requiring 20 warrants to purchase one share. VEEA and VEEAW will continue trading on the Nasdaq Capital Market, and the common stock will receive a new CUSIP.
Veea Inc. (VEEA) reports two related-party financings and a senior leadership change. On July 30 and 31, 2026, principal stockholder NLabs Inc., an affiliate of Veea’s CEO, made unsecured loans of $500,000 and $100,000 to Veea, documented as Demand Promissory Notes. Each note bears 10% annual interest, calculated on a 365‑day basis, and is payable upon the earlier of December 31, 2026 or demand, with no prepayment penalty; proceeds are for working capital.
The board terminated Chief Financial Officer and Senior Vice President Randal Stephenson without cause effective July 31, 2026, and appointed Greg Deisher, currently Chief Operating Officer and Executive Vice President, as Acting Chief Financial Officer from that date. On August 11, 2026, Veea and Mr. Stephenson entered into a Separation Agreement providing three months’ gross salary paid over six months, retention of previously vested stock options, and customary accrued compensation and expense reimbursements.
Veea Inc. entered into an At Market Issuance Sales Agreement with Roth Capital Partners LLC, allowing Veea to issue and sell shares of its common stock from time to time through or to Roth as sales agent or principal. A prospectus supplement filed on August 13, 2026 covers sales of up to $4,353,000 of common stock (the Placement Shares) under an existing effective Form S-3 registration statement.
Roth will use commercially reasonable efforts to sell shares in transactions qualifying as an “at the market offering” under Rule 415. Veea controls the maximum amount to be sold and may set minimum sale prices. Either party may suspend sales or terminate the agreement on five days’ written notice, and the arrangement ends automatically once all Placement Shares are sold. Roth is entitled to 3.0% of the gross proceeds from each sale as compensation. Veea has no obligation to sell any shares and has agreed to provide indemnification and contribution to Roth against certain liabilities.
Veea Inc. is offering up to $4,353,000 of common stock in an at-the-market program under a sales agreement with Roth Capital Partners, which will receive a 3.0% commission on gross proceeds. Shares will be sold from time to time on Nasdaq at prevailing prices.
As of August 11, 2026, Veea had 62,214,156 common shares outstanding, with a hypothetical 34,575,059 shares issuable in this program (at $0.1259) bringing total shares to 96,789,215. Management plans a 1‑for‑20 reverse stock split to address Nasdaq’s $1.00 minimum bid requirement.
The company highlights significant outstanding convertible notes, warrants and equity awards, plus recent financings including insider loans from NLabs, note conversions into preferred stock and common shares, a White Lion convertible note facility, and a secured term loan facility of up to $10,550,000. Proceeds from the ATM are earmarked for R&D, sales and marketing, and general corporate purposes, with acknowledged dilution risk to new investors.
Veea Inc. reported six-month 2026 net sales of $356,638, up from $87,168 a year earlier, and a net loss of $8,698,956 versus $3,111,806. Operating loss was $12,175,100, reflecting heavy general and administrative and product development spending.
As of June 30, 2026, total assets were $30.1 million, cash and restricted cash were $1,941,966, and total liabilities were $22,031,313, leaving stockholders’ equity of $8,050,853 after an accumulated deficit of $233.2 million. Operating activities used $11,122,601 of cash in the first half.
The company refinanced and restructured its capital, repaying a $14.0 million revolving line of credit, adding a $10.6 million secured term loan, issuing White Lion convertible notes and Series A preferred stock, and converting portions of earlier convertible notes into equity. Veea remains an emerging growth company focused on its patented VeeaONE Hybrid Edge-Cloud and Edge AI platform.
Veea Inc. describes updates to its financing arrangements with White Lion Capital LLC. Under a previously agreed Note Purchase Agreement for up to $2,500,000 of unsecured Convertible Notes and related warrants, the company completed four closings, each issuing a Convertible Note with a face amount of $555,556. Earlier closings also included warrants, such as a First Warrant to purchase 990,099 shares of common stock at an exercise price of $0.505 per share, and additional warrants sized by dividing $500,000 by the closing price of the common stock at the time.
On August 10, 2026, Veea and White Lion entered into an Amendment, Waiver and Warrant Cancellation Agreement. The First, Second and Third Warrants, covering an aggregate of 2,612,822 shares, were cancelled in connection with a regular purchase notice under the existing equity line of credit. White Lion waived rights to receive warrants at the fourth closing and any rights to a fifth closing, and the deadline for stockholder approval tied to the Note Purchase Agreement was moved to September 30, 2026. White Lion also waived its rights in connection with an at-the-market offering under Veea’s Form S-3, while Veea agreed to use commercially reasonable efforts to include White Lion’s registrable securities in its next Form S-3 registration.